tumor-specific antigens
Merck & Co. Partners with Epitopea to Explore ‘Junk DNA’ for Novel Cancer Antigens
Merck & Co., Epitopea, cancer immunotherapy, Cryptigen tumor-specific antigens, CryptoMap platform, junk DNA, off-the-shelf immunotherapies
Actionable Insights Powered by AI
Merck & Co., Epitopea, cancer immunotherapy, Cryptigen tumor-specific antigens, CryptoMap platform, junk DNA, off-the-shelf immunotherapies